regardless of promising clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable resistance from managed care entities. These insurers are typically creating limitations to coverage, including steep expense criteria and PA that limit patient availability. Analysts indicate